Mati Therapeutics Inc. is a development-stage company headquartered in Austin, Texas, focused on developing therapeutic products.
Subscribe to see Mati Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mati Therapeutics Inc. is a biotechnology company headquartered in Austin, United States. It has raised at least $14.1M across the 4 funding rounds on record. Its most recent funding round raised $9.9M in September 2025. Xcout tracks 9 named people at Mati Therapeutics Inc., including Robert Butchofsky (Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
3 more named people on record for Mati Therapeutics Inc., with roles, board committees and tenure — see the full roster →
At least $14.1M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $9.9M | — | |
| SEC Form D filing | $165,030 | — | |
| SEC Form D filing | $50,000 | — | |
| — | $4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Mati Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Ollin Biosciences is a clinical-stage biopharmaceutical holding company established in 2023 and headquartered in Austin, Texas, dedicated to developing therapeutics.
NeuroX1 Inc. is a for-profit biotechnology startup founded in 2021 with headquarters in Austin, Texas, operating a target identification and drug discovery platform that utilizes proprietary technology.
Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. Founded in 2015, the company is dedicated to revolutionizing healthcare through novel drug discovery and innovation.
Maxwell Biosciences, Inc. is a biotechnology company based in Austin, Texas. It develops biomimetic, peptide-inspired anti-infective drugs designed to act as a synthetic immune system.
Matisse Pharmaceuticals is a clinical-stage biotechnology company focused on the development of novel therapies to neutralize extracellular histones, which play a major role in severe inflammation and tissue damage. Its lead product candidate is aimed at treating life-threatening conditions such as sepsis and other acute inflammatory disorders. The company serves the medical and pharmaceutical sectors by advancing targeted treatments to improve patient outcomes in critical care settings.
Mitotherapeutix, LLC is a biotechnology company that develops small interfering RNA (siRNA) based therapeutics targeting difficult disease pathways. The company focuses on modulating mitochondrial metabolic activity by inhibiting a negative gene regulator to treat a wide array of diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Mati Therapeutics Inc.? Suggest a correction · Work at Mati Therapeutics Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.